Kamada (NASDAQ:KMDA) Share Price Passes Below 200 Day Moving Average - Should You Sell?

Key Points

• Kamada Ltd. stock price recently dropped below its 200-day moving average of $7.05, trading as low as $7.00.
• Wall Street analysts have varying ratings for Kamada, with a price target of $15.00 from Benchmark and an upgrade to "strong-buy" by Wall Street Zen.
• The company reported earnings of $0.07 per share, meeting estimates, but missed revenue expectations with $44.02 million compared to a consensus of $154.06 million for the quarter.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report)'s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $7.05 and traded as low as $7.00. Kamada shares last traded at $7.22, with a volume of 41,907 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on KMDA. Benchmark restated a "buy" rating and set a $15.00 price target on shares of Kamada in a research note on Thursday, May 15th. Wall Street Zen upgraded Kamada from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 21st. Finally, Sidoti upgraded Kamada to a "hold" rating in a research note on Thursday, May 8th.

Kamada Trading Down 2.3%

The firm has a 50 day simple moving average of $7.38 and a two-hundred day simple moving average of $7.05. The company has a market capitalization of $415.22 million, a PE ratio of 24.90, a P/E/G ratio of 0.90 and a beta of 0.93.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. Kamada had a return on equity of 6.31% and a net margin of 9.60%. The company had revenue of $44.02 million for the quarter, compared to the consensus estimate of $154.06 million. Research analysts expect that Kamada Ltd. will post 0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Huntleigh Advisors Inc. acquired a new stake in shares of Kamada in the 1st quarter valued at approximately $863,000. Geode Capital Management LLC lifted its holdings in shares of Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after buying an additional 1,549 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of Kamada in the 4th quarter valued at approximately $67,000. Aristides Capital LLC lifted its holdings in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after buying an additional 6,850 shares during the period. Finally, NewEdge Advisors LLC lifted its holdings in shares of Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after buying an additional 8,260 shares during the period. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.